https://www.nrgtherapeutics.com/wp-content/uploads/2026/09/LT_080926.jpg8001200Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-09-08 10:04:432026-09-14 10:10:15New ALS drug data reveal a mitochondrial fix
https://www.nrgtherapeutics.com/wp-content/uploads/2026/09/BioUK_040926.png7201200Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-09-04 10:03:522026-09-14 10:04:37Coulter Partners places Claus Sundgreen, M.D. as Chief Medical Officer at NRG Therapeutics
https://www.nrgtherapeutics.com/wp-content/uploads/2026/09/P_250826.jpg6501024Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-08-25 10:03:042026-09-14 10:07:30NRG5051 Targets mPTP Through Novel NLRX1 Mechanism in ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/09/DDW_250826.jpg533800Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-08-25 10:02:072026-09-14 10:02:47New drug displays anti-inflammatory and neuroprotective effects in ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/NRG-Therapeutics-spotlight-film.jpg400600Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-03-27 08:00:502026-08-14 11:19:05NRG Therapeutics CEO Spotlight Video SBC
https://www.nrgtherapeutics.com/wp-content/uploads/2026/02/ScripAsks_NRG.jpg394596Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-02-06 08:00:372026-08-14 14:55:55Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/BusinessWeekly_NRG.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-28 08:00:162026-08-14 11:19:20Founder-CEO Interview Series
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Shutterstock_657435445-1200x800-c-default.jpg8001200Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-26 08:01:292026-08-14 13:36:48Disease-modifying treatment for ALS enters Phase I
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Target-ALS.webp8001200Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-26 08:00:022026-08-14 11:36:51Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Mitochondria-1.webp350700Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-16 08:00:242026-08-14 12:44:40Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial – Target ALS
ALS Drug NRG5051 Targets Mitochondrial Pore to Protect Neurons
Longevity Pulse
Read more
New ALS drug data reveal a mitochondrial fix
Longevity.Technology®
Read more
Coulter Partners places Claus Sundgreen, M.D. as Chief Medical Officer at NRG Therapeutics
BioUK
Read more
NRG5051 Targets mPTP Through Novel NLRX1 Mechanism in ALS
Pharmacally
Read more
New drug displays anti-inflammatory and neuroprotective effects in ALS
DDW
Read more
NRG Therapeutics appoints neuroscience leader as CMO
DDW
Read more
NRG Therapeutics CEO Spotlight Video SBC
SBC
Watch now
Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
SCRIP
Read more
Founder-CEO Interview Series
Sejelas
Read more
Disease-modifying treatment for ALS enters Phase I
Drug Discovery World
Read more
Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial
Target ALS
Read more
Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial – Target ALS
ALS News Today
Read more